UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000014616 |
|---|---|
| Receipt number | R000016969 |
| Scientific Title | A early phase II study using 19 personalized peptide vaccines (KRM-19) for metastatic recurrent triple negative breast cancer patients who had been resistant to standard treatment. |
| Date of disclosure of the study information | 2014/08/01 |
| Last modified on | 2019/01/08 18:33:05 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2014/07/23 09:32:28 | ||
| 2 | Update | 2019/01/08 18:33:05 | Recruitment status Date of closure to data entry Date trial data considered complete Date analysis concluded |
